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Background: Radiation therapy is one of the recommended treatment options for localized prostate cancer. In
randomized trials, dose escalation was correlated with better biochemical control but also with higher rectal toxicity. A
prospective multicenter phase II study was carried out to evaluate the safety, clinical and dosimetric effects of the
hydrogel prostate-rectum spacer. Here we present the 12 months toxicity results of this trial.
Methods: Fifty two patients with localized prostate cancer received a transperineal PEG hydrogel injection between
the prostate and rectum, and then received IMRT to a dose of 78 Gy. Gastrointestinal and genitourinary toxicity were
recorded during treatment and at 3, 6 and 12 months following irradiation by using the RTOG/EORTC criteria.
Additionally, proctoscopy was performed 12 months after treatment and the results were scored using the Vienna
Rectoscopy Scale (VRS).
Results: Of the patients treated 39.6% and 12.5% experienced acute Grade 1 and Grade 2 GI toxicity, respectively.
There was no Grade 3 or Grade 4 acute GI toxicity experienced in the study. Only 4.3% showed late Grade 1 GI toxicity,
and there was no late Grade 2 or greater GI toxicity experienced in the study. A total of 41.7%, 35.4% and 2.1% of the
men experienced acute Grade 1, Grade 2 and Grade 3 GU toxicity, respectively. There was no Grade 4 acute GU toxicity
experienced in the study. Late Grade 1 and Grade 2 GU toxicity was experienced in 17.0% and 2.1% of the patients,
respectively. There was no late Grade 3 or greater GU toxicity experienced in the study. Seventy one percent of the
patients had a VRS score of 0, and one patient (2%) had Grade 3 teleangiectasia. There was no evidence of ulceration,
stricture or necrosis at 12 months.
Conclusion: The use of PEG spacer gel is a safe and effective method to spare the rectum from higher dose and toxicity.
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Prostate cancer is the most common cancer in older
men in the USA and Europe. The predicted 2013 pros-
tate cancer death rate in Europe is 10.5/100.000 men.
Despite treatment advances, prostate cancer still ranks
third in cancer death, after lung and colon carcinoma
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unless otherwise stated.cases in 2010 was the highest of cancers among men
in developed countries across the globe [2]. Radiation
therapy or prostatectomy are often the recommended
treatment options for localized prostate cancer [3,4]. In
patients undergoing prostate radiotherapy biochemical
control is improved with dose escalation [5]. However,
dose escalation can also increase rectal toxicity due to
the prostate - rectum proximity [6]. Although highly
conformal techniques like imaged guided radiation ther-
apy (IMRT) are able to improve dose sparing of the
rectum wall, the dose to the anterior rectal wall remains. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was able to demonstrate a direct relationship between
the volume of treated rectum and rectal toxicity [6]. The
Heemsbergen et al. publication on 553 evaluable patients
from the Dutch dose escalation trial demonstrated a cor-
relation between the acute toxicity and frequency of late
rectal toxicity [9]. Several methods have been developed
to create space between the prostate and rectum to
allow for prostate dose escalation while reducing rectal
wall irradiation [10-12]. One of these methods is a poly-
ethylene glycol (PEG) hydrogel that is injected between
the rectum and the prostate before treatment planning
and remains stable over the treatment period. A pro-
spective multicenter phase II study was carried out to
evaluate the safety, clinical, and dosimetric effects of the
hydrogel prostate-rectum spacer. Fifty-two men with
localized prostate cancer were included in this trial
[13,14]. In February 2013 Uhl et al. published the initial
clinical outcomes with acute toxicity results of the first
48 patients and late toxicity of the first 27 patients [14].
Six patients (12%) experienced acute Grade 2 GI toxicity
(no Grade 3 or 4 toxicity), while Grade 2 and Grade 3
GU toxicity was experienced in 17 (35%) and 1 (2%) of
the patients, respectively. One year after the end of ther-
apy no Grade 2 or higher GU/GI toxicity occurred. This
publication presents the results from all patients follow-
ing study completion, 12 months following completion
of EBRT and includes results of planned proctoscopic
evaluation.
Methods
As previously described 52 men with pathologically con-
firmed stage T1 or T2 prostate cancer were evaluated in
this prospective, non-randomized, multi-center, single
arm, open-label trial. The study included otherwise
healthy patients with prostates < 80 cc, PSA ≤ 20 ng/mL,
Gleason Score ≤ 6 or Gleason Score 7 with a grade 3
predominant pattern. Excluded were patients with meta-
static disease, planned pelvic lymph node radiotherapy,
prior prostate surgery, uncontrolled diabetes, chronic
systemic corticosteroid therapy, prior prostate or pelvis
radiation therapy, active bleeding disorder, historical or
active inflammatory bowel disease, or a history of rectal
or gastrointestinal surgery. Androgen deprivation ther-
apy was not an exclusion criteria. Following local Ethics
Committee approvals patients were enrolled at the
University of Heidelberg (n = 21), University of Aachen
(n = 20), NKI-AVL Nederlands Kanker Instituut Amsterdam
(n = 7) and University of Geneva (n = 4).
After Informed Consent and documentation of medical/
surgical history patients underwent a baseline computed
tomography (CT) simulation scan to generate a baseline
external beam radiation treatment plan. Subjects then
underwent transperineal injection of SpaceOAR hydrogelin a procedure previously described by Hatiboglu et al.
[15]. Briefly, via a transperineal approach an 18G needle
was advanced using transrectal ultrasound guidance
into the perirectal fat at prostate midgland, and saline
was injected to expand the potential space between
Denonvilliers’ Fascia and the anterior rectal wall. With
the needle in the same location, 10 – 30 ml of Space-
OAR hydrogel precursors (Augmenix, Waltham, MA,
USA) were injected into the same space where they
polymerize within 10 seconds to form an absorbable
hydrogel spacer (up to 30 ml was applied in several
early patients, while the majority of patients received
10 ml). The mean procedure time for this application
was 6.3 minutes [15]. After injection, a second scan for
treatment planning was carried out (Figure 1). Patients
then received 78 Gy of radiation delivered by IMRT
technique over an 8-week period, 2 Gy per fraction, at
5 fractions per week. The clinical target volume (CTV)
included the gross tumor volume (GTV) and, per the
treating physician’s discretion, the proximal 2/3 of the
seminal vesicles. Planning tumor volumes (PTV) in-
cluded the CTV plus a 4–10 mm margin to compensate
for daily setup variability and internal organ motion,
with 5 mm or less posterior expansion. The guidelines
for whole rectum V70 and bladder V70 tissue con-
straints were < 25% and < 40%, respectively. At least
99% of the PTV had to receive at least 95% of the pre-
scription dose. A maximum dose less than 107% of the
prescription dose was required. The dosimetric results
of this trial were published by Song et al. [13]. Since
the hydrogel produced a perirectal space ≥7.5 mm in
95.8% of the patients, the rectal V70 was reduced ≥ 25%
in 95.7% of the patients, with a mean reduction of 8 Gy
[13]. Acute rectal (GI) and genitourinary (GU) toxicity
(RTOG/EORTC criteria as described by Cox et al.) [16]
were recorded weekly during IMRT and at a visit 3
months following IMRT. Late GI and GU toxicity was
similarly assessed at visits 6 and 12 months following
IMRT completion. Additionally at 6 months post IMRT
patients underwent MRI scans to assess hydrogel ab-
sorption, and at 12 months post IMRT, PSA levels were
measured and proctoscopy was performed. Procto-
scopic observations of congested mucosa, telangiecta-
sia, ulceration, stricture and necrosis were scored using
the Vienna Rectoscopy Scale [17].
Results
The average age of patients enrolled in this study was
68.9 ± 8.0 years, with the average time since initial
prostate cancer diagnosis being 110 ± 140 days. Fifty four
percent of the patients had T1 stage (2% T1a, 2% T1b,
50% T1c), with the remaining having T2 stage (6% T2,
17% T2a, 17% T2b, 6% T2c). Average patient PSA was 6.9
(range 0.1 - 19.8), with Gleason score 6 and 7 (Grade 3
Figure 1 Dose distribution a) pre- and b) post injection of spacer gel.
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Prostate volume in study patients was 56.9 ± 20.4 cc.
There were four patients excluded from the per-protocol
population (n = 48) due to no hydrogel injection (n = 2),
inadvertent rectal wall injection (n = 1) and improper
polymer reconstitution (n = 1). These events took place
early in the study and were addressed with previously
published procedural modifications [14]. The rectal wall
injection resulted in focal rectal mucosal necrosis which
completely resolved with no further sequelae, while the
improper polymer reconstitution resulted in no gel for-
mation and no patient complications. Additionally, one
patient withdrew from the study resulting in 47 patients
in the late follow up population. These 12 months post
treatment follow up toxicity results represent the final
evaluation of previously published collective. A total of
19 (39.6%) and 6 (12.5%) patients experienced acute
Grade 1 and Grade 2 GI toxicity, respectively (Table 1).
There was no Grade 3 or Grade 4 acute GI toxicity
experienced in the study. A total of 45 (95.7%) patients
experienced no late GI toxicity (95.7%), with 2 (4.3%)
patients experiencing late Grade 1 GI toxicity. There
was no late Grade 2 or greater GI toxicity experienced
in the study. A total of 20 (41.7%), 17 (35.4%) and 1Table 1 Acute and late GI/GU toxicity (Maximum score)




Acute Late Acute Late
0 23 (48.0%) 45 (95.7%) 10 (21.0%) 38 (80.9%)
1 19 (39.6%)1 2 (4.3%)2 20 (41.7%)3 8 (17.0%)4
2 6 (12.5%) 0 (0%) 17 (35.4%)5 1 (2.1%)
3 0 (0%) 0 (0%) 1 (2.1%) 0 (0%)
4 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 1 or worse 25 (52.1%) 2 (4.3%) 38 (79.2%) 9 (19.1%)
Grade 2 or worse 6 (12.5%) 0 (0%) 18 (37.5%) 1 (2.1%)
11 subject was Grade 1 at Baseline, 21 subject was Grade 1 at Baseline,
33 subjects were Grade 1 at Baseline, 46 subjects were Grade 1 at Baseline,
53 subjects were Grade 1 at Baseline, 1 subject was Grade 2 at Baseline.(2.1%) patients experienced acute Grade 1, Grade 2 and
Grade 3 GU toxicity, respectively (Table 1). There was
no Grade 4 acute GU toxicity experienced in the study.
A total of 8 (17.0%) and 1 (2.1%) patients experienced
late Grade 1 and Grade 2 GU toxicity, respectively.
There was no late Grade 3 or greater GU toxicity experi-
enced in the study. The mean prostate to rectum dis-
tance at prostate midgland was 9.7 ± 5.5 mm following
hydrogel injection, 10.5 ± 5.3 mm following completion
of IMRT, and 2.9 ± 4.2 mm three months following com-
pletion of IMRT, reflecting hydrogel absorption. MRI
scans to assess hydrogel absorption were obtained in 44
patients 6 months following IMRT. Aside from a small
amount of absorbing gel in one patient (2.3%), hydrogel
was found to be completely absorbed in every case.
Forty-five (45) of 47 patients (95.7%) in the Per-Protocol
Population underwent proctoscopic exams at 12 months
following completion of EBRT. Of the 45 subjects evalu-
ated, 32 patients (71%) had a VRS score of 0. Grade 2
congested mucosa was noted for 1 subject (3%) and tel-
angiectasia was found in 28% of subjects: 13% Grade 1,
13% Grade 2, and 2% for Grade 3. There was no evi-
dence of ulceration, stricture or necrosis at 12 months.
PSA values at 12 months post EBRT are available for 45
subjects. Every patient showed a decreasing PSA value
after treatment. No incidence of PSA relapse could be
observed one year after irradiation. The mean PSA at 12
months post EBRT was 0.99 ± 0.09 ng/mL, which repre-
sents a decrease of 5.87 ± 4.23 ng/mL compared to
baseline.
Discussion
While studies have demonstrated that dose escalation
improves local control in men with prostate cancer, con-
cerns of rectal toxicity limits implementation [6,8]. Thus,
a meaningful dose escalation is only possible with a bet-
ter sparing of rectal tissue. Conformal techniques such
as brachytherapy, IMRT and proton therapy are helping
to resolve this problem. Despite improvements in dose
conformity, intra-fraction prostate motion can move the
Figure 2 Comparison of gastrointestinal toxicity ≥Grade 2 with other trials. Lips et al. [18]: PTV = Prostate + seminal vesicles + 8 mm margin,
76 Gy mean dose, not more than 5% of rectum received≥ 72 Gy. Vora et al. [19]: PTV = Prostate + seminal vesicles + 6-10 mm margin, 50.4 Gy +
Boost (median 75.6 Gy), not more than 40%/30%/10% of Rectum received≥ 65 Gy/70 Gy/75 Gy, not more than 1.8 cm2 of rectum received 81 Gy.
Zietman et al. [8]: PTV = Prostate + seminal vesicles + 10mm margin for Photontherapy (50.4 Gy) and 5mm margin for proton Boost (28.8 GyE).
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of the irradiated volume posterior to the prostate is not
a good solution, since most prostate cancers in the per-
ipheral zone of the gland, occur adjacent to the rectum.
A very simple and logical solution is to create more dis-
tance between the required volume to be irradiated and
the anterior portion of the prostate. This can be easily
achieved with the injection of a spacer between the rec-
tum and prostate to create and maintain space through-
out treatment. The feasibility and effectiveness of the
hydrogel injection were objectives of this study. It has
already been demonstrated that the injection procedure
is safe and a stable 1 cm distance between the prostate
and the rectum can be generated [15] resulting in a
significant dose reduction to the rectum [13]. The
prospectively collected data show a very low GI acute
toxicity with only 12.5% Grade 2, and no Grade 3 orFigure 3 Comparison of Vienna rectoscopy scores at 12 months for mhigher toxicity. A total of 95.7% of patients had no late
GI toxicity and only 4.3% (n = 2) had late Grade 1 GI
toxicity. After completion of the follow up time, these
results validate our published data with early results
[14]. Despite some differences in margins and dose
delivered, the lower GI toxicity rates in this study are
remarkable when compared to other studies (Figure 2)
[8,18,19]. Like a number of other toxicity reports, proc-
toscopy was also performed 12 months after the end of
therapy [17]. Ippolito et al. could show that early proc-
toscopy 12 months after irradiation can be used as a sur-
rogate endpoint for late rectal toxicity. The incidence of
late rectal toxicity ≥ grade 2 was higher in patients with
VRS score grade ≥2 or 3 [20]. In our results no evidence
of ulceration, stricture or necrosis was found. Seventy
one percent of patients had a VRS score 0, with 13% and
2% having Grade 2 and Grade 3, respectively. Anotheren treated with SpaceOAR vs. the literature [21].
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correlation between VRS and EORTC/RTOG score 12
months after prostate irradiation with 70 or 74 Gy [21].
At 12 months following IMRT the pathological changes to
rectum mucosa in this hydrogel spacer trial are less that
in the Goldner et al. prospective trial, despite the higher
radiation dose in this hydrogel spacer study (Figure 3).
Other studies with spacer between the rectum and pros-
tate show similar toxicity reductions. Noyes et al. evalu-
ated human collagen injections into the perirectal space
and found a subsequent reduction of GI toxicity in
patients compared with a historical control group [10].
Wilder published similar results after hyaluronic acid
injection [12]. The PEG gel in our study was stable dur-
ing treatment and was reabsorbed within a year. The
patients in this hydrogel trial experienced 41.7%/35.4%/
2.1% Grade 1/2/3 acute GU toxicity, respectively. A
total of 35% and 2% had Grade 1 and Grade 2 GU
toxicity at 12 months after treatment. No ≥Grade 3 GU
toxicity was experienced in this trial. Thus, the rate of
patients with GU toxicity ≥ 2 is favorable compared to
studies without spacers [8,18,19]. Despite the added
cost of the product, routine incorporation of hydrogel
may result in significant overall health system savings as a
result of decreased toxicity and less frequent need for
proctitis treatment, fewer treatment fractions (hypofrac-
tionation) may be made even more safe and, potentially, a
lower rate of cancer recurrence (dose escalation).
Conclusion
The use of PEG spacer gel is a safe and effective method
to spare the rectum from higher dose and toxicity. Due
to fewer late side effects on the rectum, along with the
potential of enabling hypofractionation and dose escal-
ation, the hydrogel spacer may lead to lower costs for
the healthcare system.
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